Genetic Frontotemporal Dementia Initiative (GENFI)
GENFI investigates both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry an abnormal genetic mutation. By studying these individuals who are destined to develop the disease later in life we can understand the development from the very earliest changes. The key objectives of GENFI are therefore to develop markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked.
Prospective Study of Single Subject Cortical Thickness as an Early Diagnostic Biomarker of Frontotemporal Dementia
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Ionis ISIS 814907-CS1
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients with Mild Alzheimer’s Disease
Centre de recherche de l’IUGM
Quantitative Magnetic Resonance Imaging of oxygen transport: a new window on mitochondrial dysfunction in Alzheimer’s disease, Phase 3: data acquisition in individuals affected by Alzheimer’s disease and demographically-matched control participants.